InVivoMAb anti-rat/mouse CD71 (TfR1)
Useful for targeted drug delivery to the brain
?
研發(fā)背景：?
OX-26單克隆抗體可識別大鼠的CD71蛋白，CD71蛋白也被稱為轉(zhuǎn)鐵蛋白受體蛋白1（TfR1）。據(jù)報(bào)道，該抗體OX-26也與小鼠CD71發(fā)生交叉反應(yīng)。CD71是一種170-180kda的II型同型二聚體跨膜糖蛋白，其表達(dá)于增殖細(xì)胞、網(wǎng)狀細(xì)胞和類紅細(xì)胞前體等細(xì)胞的表面。
?
CD71在調(diào)節(jié)細(xì)胞增殖中起著重要作用，它是通過細(xì)胞內(nèi)吞作用將鐵從轉(zhuǎn)鐵蛋白轉(zhuǎn)運(yùn)到細(xì)胞內(nèi)的。有研究表明，CD71在惡性腫瘤細(xì)胞中高水平表達(dá)，其表達(dá)與腫瘤的進(jìn)展有關(guān)。這種在惡性細(xì)胞上的高表達(dá)，加上CD71的內(nèi)化能力以及鐵對癌細(xì)胞增殖的必要性，會使轉(zhuǎn)鐵蛋白受體成為一個有吸引力的靶點(diǎn)，可用于將藥物輸送到惡性細(xì)胞。OX-26與CD71的胞外結(jié)構(gòu)域結(jié)合后，通過內(nèi)源性轉(zhuǎn)鐵蛋白轉(zhuǎn)運(yùn)系統(tǒng)進(jìn)入血腦屏障（Blood-Brain Barrier，BBB）。在這一機(jī)制下，OX-26抗體常被用于在實(shí)驗(yàn)性大鼠模型中通過BBB轉(zhuǎn)運(yùn)結(jié)合藥物。
?
??抗體的應(yīng)用
◎?腦部的靶向給藥
◎?冰凍切片的免疫組化實(shí)驗(yàn)
◎?流式細(xì)胞術(shù)
?
??一如既往，BioXcell抗體是專為體內(nèi)使用而制備的，具有以下特點(diǎn)：
◎?95%純度
◎?超低內(nèi)毒素水平
◎?不含防腐劑、穩(wěn)定劑和載體蛋白
?
??產(chǎn)品信息：??
產(chǎn)品貨號 | BE0331 |
產(chǎn)品名稱 | InVivoMAb anti-rat/mouse CD71 (TfR1) |
規(guī)格 | 1mg、5mg、25mg、50mg、100mg |
克隆號 | OX-26 |
同種型(Isotype) | Mouse IgG2a, κ |
免疫原(Immunogen) | PHA-activated PVG rat lymph node cells |
成分(Formulation) | PBS, pH 7.0 |
Contains no stabilizers or preservatives |
內(nèi)毒素(Endotoxin) | <2EU/mg (<0.002EU/μg) |
Determined by LAL gel clotting assay |
純度(Purity) | >95% |
Determined by SDS-PAGE |
無菌(Sterility) | 0.2 μM filtered |
生產(chǎn)(Production) | Purified from tissue culture supernatant in an animal free facility |
純化(Purification) | Protein A |
保存(Storage) | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
應(yīng)用(Reported Applications) | Targeted drug delivery to the brain |
Immunohistochemistry (frozen) |
Flow cytometry |
?
??Application References:??
Amani, H., et al. (2019). 'Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling.' Sci Rep 9(1): 6044.?
Tang, X., et al. (2015). 'Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity.' Int J Nanomedicine 10: 6227-6241?
Yue, J., et al. (2012). 'Fluorescence-labeled immunomicelles: preparation, in vivo biodistribution, and ability to cross the blood-brain barrier.' Macromol Biosci 12(9): 1209-1219.?
Fabriek, B. O., et al. (2007). 'The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor.' Blood 109(12): 5223-5229.?
Jimenez, E., et al. (2002). 'Rat peripheral CD4+CD8+ T lymphocytes are partially immunocompetent thymus-derived cells that undergo post-thymic maturation to become functionally mature CD4+ T lymphocytes.' J Immunol 168(10): 5005-5013.
詳情請咨詢 BioXcell 中國授權(quán)代理-欣博盛生物科技
全國服務(wù)熱線: 4006-800-892 ???????????郵箱: market@neobioscience.com
深圳: 0755-26755892 ?????北京: 010-88594029 ?????上海: 021-34613729 ?????????
廣州：18024516375 ???????香港: 852-69410778
代理品牌網(wǎng)站: www.nbs-bio.com
自主品牌網(wǎng)站: www.neobioscience.net